Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Takeda Pharmaceutical Company Limited before investing.

In this article, we go over a few key elements for understanding Takeda Pharmaceutical Company Limited’s stock price such as:

• Takeda Pharmaceutical Company Limited’s current stock price and volume
• Why Takeda Pharmaceutical Company Limited’s stock price changed recently
• Upgrades and downgrades for TAK from analysts
• TAK’s stock price momentum as measured by its relative strength

About Takeda Pharmaceutical Company Limited (TAK)

Before we jump into Takeda Pharmaceutical Company Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Want to learn more about Takeda Pharmaceutical Company Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited’s Stock Price as of Market Close

As of May 08, 2025, 12:47 PM, CST, Takeda Pharmaceutical Company Limited’s stock price was $14.375.

Takeda Pharmaceutical Company Limited is down 4.55% from its previous closing price of $15.060.

During the last market session, Takeda Pharmaceutical Company Limited’s stock traded between $14.215 and $14.830. Currently, there are approximately 10.08 million shares outstanding for Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited’s price-earnings (P/E) ratio is currently at 18.2, which is high compared to the Pharmaceuticals industry median of 17.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Takeda Pharmaceutical Company Limited Stock Price History

Takeda Pharmaceutical Company Limited’s (TAK) price is currently down 5.98% so far this month.

During the month of May, Takeda Pharmaceutical Company Limited’s stock price has reached a high of $15.430 and a low of $14.215.

Over the last year, Takeda Pharmaceutical Company Limited has hit prices as high as $15.425 and as low as $12.575. Year to date, Takeda Pharmaceutical Company Limited’s stock is up 8.57%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Takeda Pharmaceutical Company Limited Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2025, there were analysts who downgraded Takeda Pharmaceutical Company Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Takeda Pharmaceutical Company Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Takeda Pharmaceutical Company Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Takeda Pharmaceutical Company Limited’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Takeda Pharmaceutical Company Limited (TAK) by visiting AAII Stock Evaluator.

Relative Price Strength of Takeda Pharmaceutical Company Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2025, Takeda Pharmaceutical Company Limited has a weighted four-quarter relative price strength of 5.11%, which translates to a Momentum Score of 74 and is considered to be Strong.

Want to learn more about how Takeda Pharmaceutical Company Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Takeda Pharmaceutical Company Limited Stock Price: Bottom Line

As of May 8, 2025, Takeda Pharmaceutical Company Limited’s stock price is $14.375, which is down 4.55% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Takeda Pharmaceutical Company Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.